Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: J Invest Dermatol. 2014 Apr 14;134(9):2438–2446. doi: 10.1038/jid.2014.186

Figure 4. CD11b+ Gr1int F4/80+ Ly6GlowLy6Chi cells produce arginase in DNCB treated K14.E7 skin.

Figure 4

Arginase activity produced by CD45.2+CD11b+ and CD45.2+CD11b− populations from DNCB treated C57BL/6 and K14.E7 mice (a) was determined as described in Materials and Methods. Arginase-1 and arginase-2 mRNA expression (b) was determined by real-time PCR. Arginase-1 mRNA expression in Gr1−F4/80+; Gr1intF4/80+; Gr1hiF4/80+ and Gr1−F4/80− subsets from DNCB treated K14.E7 mice was determined (c) by real time PCR. Real time PCR analysis of arginase-1 mRNA expression in different cell subsets (d) was based on the expression of Ly6C and Ly6G antigens. Data were pooled from four independent experiments. In each experiment, six C57BL/6 and two K14.E7 mice were treated with DNCB or vehicle. Means ± SEM. *p<0.05, **p<0.01, *** p<0.001, ns= not significant.